ArticleClinical pharmacology and therapeutics2026
Phase I Evaluation of Siltartoxatug, a First-in-Class Anti-Tetanus Monoclonal Antibody: Safety, Pharmacokinetics and Pharmacodynamics in Healthy Australian and Chinese Populations.
Xinyu Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.